Objectives Early tumor shrinkage (ETS) has been reported to be associated with survival of metastatic colorectal cancer (mCRC) patients. Our aim was to analyze long-term tumor-size evolution, according to early mCRC best responses during the first-line therapy, to evaluate first best response-survival links.
Introduction
Metastatic colorectal cancer (mCRC) management now achieves longer overall survival (OS), reaching 30 months in recent phase III trials [1] [2] [3] [4] . For fit patients, first-line treatments are based on doublet or triplet chemotherapy combined with a targeted agent. Anti-angiogenic bevacizumab is approved for all patients, whereas panitumumab and cetuximab, which target the epidermal growth factor receptor (EGFR), are limited to the subgroup of patients with RAS (a gene mutation predictive of the non-efficacy of anti-EGFR) wild-type mCRC [5] . At present, the choice of first-line regimen is guided by RAS status and the aim of obtaining tumor shrinkage for patients with symptomatic disease or potentially resectable metastases [5] .
In general, clinical trials evaluate chemotherapy efficacy by OS, progression-free survival (PFS), and tumor objective response rate (ORR). PFS is often used as a surrogate criterion for OS, as an early endpoint. Tumor response is evaluated by ORR, assessed with the revised response evaluation criteria in solid tumors (RECIST criteria (version 1.1) [6] ) that clinicians also use extensively in routine practice to adapt their therapeutic strategies.
The validity of PFS as a surrogate endpoint for OS in mCRC is questioned [7, 8] , as median OS now exceeds 30 months, but PFS is still about 10 months. In addition, in a phase III trial that compared doublet chemotherapy plus anti-EGFR or bevacizumab (FIRE-3) [3] , median PFS did not differ between arms, whereas an OS benefit in favor of anti-EGFR was still found. One of the hypotheses to explain this OS-PFS discordance is the efficacy of subsequent chemotherapy lines. Another hypothesis is that other responserelated outcome parameters, such as early tumor shrinkage (ETS) and depth of response, could have made an OS difference, despite comparable PFS [9] . ETS and depth of response are indicators of precociousness and intensity of tumor-size response to therapy and predictors of OS and PFS [10, 11] . ETS (depending on its definition) is achieved when the tumor load has decreased 10-30% [12] , as measured at the time of first imaging control, between 6 and 8 weeks after starting treatment. Depth of response is defined as the percentage of tumor shrinkage, based on the sum of the longest diameters, observed at the time of the lowest value (nadir) compared to before starting therapy (baseline). ETS and depth of response have since been validated retrospectively by several prospective trial results [11, [13] [14] [15] [16] [17] .
The tumor-size evolution in response to first-line therapy (henceforth initial response) has been particularly studied as a predictor of OS and PFS [15, 18] , but its impact on responses to subsequent treatment lines has never been investigated. Only radiological data on first-line therapy were available in those retrospective analyses. Hence, evolution under successive lines remains hypothetical [12] .
Our aim was to analyze tumor-size evolution over the long term, according to the early mCRC initial responses, to explore the link between initial tumor-size evolution and OS.
Methods

Patients
Ethics committee approval was waived for this single-center retrospective study.
All the patients treated in our center for unresectable mCRC, between 1 January 2010 and 30 January 2015, were identified by computer search of the chemotherapyprescription software. We included only conventional adenocarcinomas (excluding mucinous tumors) treated by cytotoxic and targeted chemotherapies. None of them were treated with immunotherapy. Patients with at least one measurable lesion, according to the RECIST 1.1 criteria [6, 19] , were included. Target lesions were defined at baseline, and the largest diameter had to be ≥ 10 mm or short-axis ≥ 15 mm if the lesion was a lymph node.
We excluded patients: (1) with no available baseline computed tomography (CT) scan and patients with fewer than five reevaluation CT scans; (2) with no target lesions according to RECIST 1.1 criteria or with target lesions that could not be followed over the long term, especially after secondary metastatic liver resection; and (3) without sufficient clinical follow-up information (on different chemotherapy lines or outcome).
Image analysis and clinical information
All but 10 baseline scans and all follow-up scans were performed in our institution using two CT systems, with 2 × 128-detector rows (ICT 256, Philips healthcare) or with 128-detector rows (ICT 128, Philips healthcare). The acquisition were done according to the actual standard, without and after an intravenous injection of 2 ml/kg body weight of an iodinated contrast agent (2.5 ml/s) at 350 mg of iodine/ml, during the arterial phase (35 s; slice thickness, 1.5 mm) at the thoracic level, and during the portal phase (70 s; slice thickness, 2 mm) at the abdominal and pelvic levels. Tumor-size evolution was evaluated by CT scan according to the RECIST criteria [6] , with a first evaluation at 8 weeks, then every 8-12 weeks. RECIST criteria are based on the largest target lesion diameters combined with a subjective assessment of non-target lesions. Target lesions are defined on the baseline CT scan. On follow-up images, the target lesion response is evaluated as the percentage change of the sum of their largest diameters against baseline or subsequent scan with the lowest sum of target disease (nadir). The ORR is defined as the sum of complete (disappearance of all target lesions) and partial responses (PR, ≥ 30% decrease of the sum of target lesion diameters, compared to baseline). Progressive disease (PD) is ≥ 20% increase of the sum of target lesion diameters, with the smallest study sum (including baseline) serving as the reference. Stable disease (SD) is neither response nor PD.
The first CT scan analyzed was always the baseline examination just before the first-line therapy. A maximum of five target lesions could be chosen, with a maximum of two per organ. When analyzing a follow-up scan, the same target lesions were measured and their sum was again calculated. Two radiologists (O.L. and A.F., with 25 and 2 years of experience, respectively), blinded to each patient's clinical findings and previous radiology reports, retrospectively analyzed the CT images by consensus. Response to therapy was assessed manually using the PACS Carestream (Carestream Health).
Clinical information (patient characteristics, tumor characteristics, chemotherapy lines, responses to chemotherapy, and outcome) was collected from each patient's electronic or paper medical chart by the oncologist (L.-J.P.).
Analytical groups
Patients were separated into five groups according to their best responses to first-line (fl) chemotherapy, defined as follows: ETS fl , ≥ 30% tumor reduction at 8 weeks; PR fl , ≥ 30% tumor reduction but without ETS fl (delayed response); SD fl + or SD fl -, respectively, with tumor-size evolution between + 1 and + 19% or 0 and − 29%; and PD fl , ≥ 20% tumor growth and/or appearance of new lesion(s). Figure 1 is an example of a radiological evaluation.
Long-term tumor-size evolution
For each patient, we used the RECIST criteria customized for this study as follows: First, we focused only on the target lesions, not taking into account the non-target lesions. Second, the largest diameters of the initial target lesions on every reevaluation CT scan, from baseline to death or end of follow-up, were summed. Target lesions were not modified when chemotherapy changed. To display the results, we considered the sum of the first-line baseline CT scan's target lesions to be 100%, and the evolution of the sum of the largest diameter(s) at each of the subsequent CT scans, regardless of different chemotherapy lines, was systematically assessed as a percentage of variation from that first-line baseline 100%. To avoid, as much as possible, bias induced by the appearance of new lesions, we systematically added 20% to the curve when new lesions were identified. We choose arbitrarily 20% because this increase defines progression according to the RECIST criteria as the appearance of new lesion does. Finally, to easily visualize deaths and to distinguish non-survivors from survivors or censored in one readable graph, we arbitrarily represented death visually as top line on the graph reached by each patient's curve. We analyzed the tumor burden (the sum of target lesions) at endpoint, defined as the last reevaluation CT scan.
Response to each new chemotherapy line
In a second analysis, the evolution of the sum of the largest diameters at the time of the best response was systematically assessed as a percentage of variation from the corresponding baseline for each new chemotherapy line. Each baseline was thus considered 100%, independently from the baselines of the previous chemotherapy lines. Hence, graphically, a return to 100% means a treatment line change. This analytical methodology yielded a Bsawtoothed^line for each patient. Each new treatment line was defined as a change of chemotherapy or targeted agents. Unlike the analysis of the tumor-size evolution over the long term, death is not represented on the graph. Maintenance therapies and reintroduction of the first-line cytotoxic agent(s) after progression under maintenance were not considered a new line. We evaluated secondand third-line ORRs, defined as best responses to therapy (sum of complete and PRs) and the disease-control rate (sum of complete responses, PRs, and SDs).
Statistical analyses
Quantitative variables are summarized using descriptive statistics: number of patients with available data (n) or mean ± standard deviation and compared with ANOVA test. Qualitative variables are expressed by arm as n (%) and compared with chi-squared test with the Yates correction for small sample sizes.
Survival rates, estimated with the Kaplan-Meier method, are expressed as median (95% confidence interval (CI)) duration, and compared using the log-rank test. OS lasted from the date of the first administration of the first-line regimen to that of death (all causes). PFS was defined as the time from the date of the first administration of the first-line regimen and to that of progression or death. Survivors without progression were censored on the date of the most recent information update. The cut-off date for the final data analysis was 15 November 2016.
Statistical analyses were computed with R software, with statistical significance set at p value < 0.05.
Results
Population studied
Among the 226 potentially eligible patients (Fig. 2) , 161, whose lesions could not be followed over the long term, were excluded; the final analysis concerned the 65 patients with complete radiological and clinical follow-up information available. According to the radiological review, patients' best responses at first line were scored as follows: 14/65 (22%) The global characteristics of the 65 patients and according to their five groups, defined by their initial tumor ORRs, are described in Table 1 . No significant differences were found between the five groups for sex ratio, age, primary tumor and the metastatic sites, mutational status, tumor differentiation, and the type of first-line therapy. Only the microsatellite instability (MSI) status distribution differed significantly among the five groups (p = 0.02), with the ETS fl group having more microsatellite stability (MSS).
Long-term tumor-size evolution and clinical outcomes
Spider plots of individual patient's tumor-size evolution, appearance of new lesions over the long term, and death as assessed with our customized RECIST criteria, according to initial best response group, are represented in Fig. 3 . Clinical outcomes (Death, OS, PFS) and tumor burdens at endpoint and death are reported in Table 2 .
Among the patients with PD fl or SD fl +, 12/14 (86%) had target lesion sums superior to their first baseline assessment at endpoint (dead or alive), as opposed to 18/51 (35%) patients with ETS fl or PR fl or SD fl -(p < 0.001). Considering death as the only endpoint, 11/12 (92%) patients with PD fl or SD fl + died with lesion sums superior to their initial baseline, whereas for patients with ETS fl , PR fl , or SD fl -, only 15/37 (41%) did (p < 0.01).
OS also differed significantly among groups (p = 0.03), being longer for the ETS fl group (median OS, 29.9 (95% CI, 12.6-47.1) months) and shorter for the PD fl group (median OS, 17.1 (95% CI, 1.5-37.5) months). Median PFS lasted 15 (95% CI, 9.8-24.2) months for the ETS fl group vs 2.9 (95% CI, 4.9-15.3) months for the PD fl group; however, the between-group difference did not reach significance (p = 0.3).
Response to each new chemotherapy line
Individual patient's best responses to each chemotherapy line, according to his/her initial response, are represented in Fig. 4 . Response and disease-control rates to second-and third-line therapies are detailed for each initial response group in Table 3 . Visually, tumor responses to successive lines differed substantially, depending on the initial response. Patients with ETS fl had more negative peaks below baseline 100%, and SD fl + or PD fl patients had more positive peaks above that baseline for successive treatments. In other words, patients with an initial response to first-line chemotherapy tended to have a response to the following lines of chemotherapy, whereas patients who progressed initially tended to also not respond to following lines. This tendency was not statistically significant due to the small number of patients in each group. 
Discussion
Assessing tumor responses with ETS and depth of response was recently shown to be associated with better OS and PFS outcomes [12] , but only responses to first-line therapy were reported. Herein, we focused on the impact of the initial responses on long-term outcomes. Two mCRC evolution types were distinguished. First, mCRCs with ETS fl , PR fl or SD fl -, which maintained low tumor loads (only 41% of patients died with tumor sizes superior to baseline), had better responses to subsequent therapy lines. Their initial tumor ORR was significantly associated with longer OS. Indeed, that beneficial response to first-line chemotherapy seemed to be prolonged over time, under successive lines. Second, mCRCs with PD fl Results are expressed as n (%) or survival (95% confidence interval (CI)). Between-group differences were significant for OS (p = 0.03), but not for PFS (p = 0.3)
ETS fl early tumor shrinkage, PR fl partial response, SD fl stable disease, PD fl progressive disease or SD fl +, whose tumor loads rose (91% died with a target lesion sums superior to their baseline assessment), continued to be mostly refractory to later therapy lines. Our results are in accordance with those of the analysis of the role of tumor-size reduction in response to first-line therapy as a predictor of mCRC patients' long-term outcomes [12, 14] . ETS, defined a ≥ 20% or 30% response, was proved to be associated with better PFS and OS after doublet chemotherapy with an anti-EGFR [9, 13, 15, 17, 20, 21] , and after bevacizumab with triplet or double chemotherapy [14] . In the literature, patients with ETS, compared to those without, had maximum ΔPFS of 7.6 months and maximum ΔOS of 33.8 months. Those findings are summarized in Table E1 (online). We also described tumor-size evolution after this early response to chemotherapy, which had not been studied previously. Even outside a clinical trial, an early first CT scan reevaluation with RECIST criteria between 6 and 8 weeks seems crucial to determine long-term mCRC evolution. Notably, we found that the initial response might be suggestive of future responses to later lines of therapy and, hence, longer OS and PFS. Explanations that can be put forward are as follows: On the one hand, initial intrinsic tumor aggressiveness remains constant or worsens, regardless of the chemotherapy prescribed. Indeed, changing the chemotherapy did not visibly impact the factors responsible for that aggressiveness. On the other hand, less aggressive tumors maintain a favorable profile in response to different types of chemotherapy, even after resistant clone selection by the previous lines. This observation suggests that some aggressiveness factors are independent, or unaffected, by the different chemotherapy lines currently being used. This hypothesis raises the question of whether or not to pursue chemotherapy for mCRCs with initial progression at the first CT reevaluation at 8 weeks. Indeed, these tumors with immediate progression, which represent 10% of mCRCs, do not seem to respond to the successive chemotherapies and have very little chance of later disease control. This issue should be evaluated prospectively, comparing best supportive care alone to best supportive care plus chemotherapy, but conducting such a study is complicated, for ethical reasons.
Our study has some limitations. First, our single-center study included a relatively small number of patients, only 65, but all had fully documented clinical and radiological (at least five reevaluation scans) follow-up. Indeed, we excluded many potential subjects because CT scans were not available to analyze the evolution from the first scan to death. Our study population was, however, quite representative of mCRCs with, at the first reevaluation: 49.2% ETS fl or PR fl responders, 41.5% SD fl and 9.2% PD fl , rates similar to those published previously [2, 3] . Also, the five groups' characteristics were quite similar. Second, the representation of new lesions is another potential limitation. Indeed, we chose to represent new lesions by systematically adding 20% to each patient's curve, which could be too much or too little. In addition, we did not consider non-target lesions, even though we know that the tumor burden sometimes increases due to the non-target lesions and not because of preexisting target lesions that can become necrotic or fibrotic. Hence, following the same lesion through the different chemotherapy lines may underestimate the true tumor-burden evolution. However, bias would be similar for all groups and does not explain the differences we found. Third, we did not analyze tumor-size responses according to treatment regimen for the different groups, because heterogeneous chemotherapies were used and more patients would be required to obtain meaningful information. Fourth, we decided arbitrarily to split into two parts the RECIST Bstable diseaseĝ roup. Our aim was to consider separately the outcome of all the patients with an initial positive slope for their lesion size evolution (i.e., PD fl and SD fl +) and those with a negative slope (i.e., SD fl −, PR fl , and ETS fl ). However, even if our results suggest that the SD group gathers patients with different evolutive profiles, this is based on a small cohort and further studies are needed to confirm this point.
Fifth tumor response assessment was done by two radiologists by consensus; consequently, no interobserver agreement can be known; however, we did not study or use nonvalidated methods to assess the tumor responses.
Analyses of long-term tumor-size evolutions according to early response to first-line chemotherapy could be applied to larger populations in multiple centers with mathematical modeling of those evolutions. In addition, in the near future, we should be able to assess tumor evolution reliably and even earlier with circulating tumor DNA. Indeed, an early change of the latter's concentration could be a marker of therapeutic efficacy in mCRC patients, as recently assessed in two prospective studies [22, 23] .
In conclusion, a response to first-line chemotherapy was associated with the selection of chemosensitive mCRCs, future responses to subsequent treatment lines, and longer OS. An initial lack of response or PD fl was associated with tumors refractory to successive therapy lines with rising tumor loads. Tumorsize evolution according to the initial response to first-line chemotherapy may thus predict survival. These findings reinforce the interest of an early tumor reevaluation, eight weeks after baseline CT assessment, to predict long-term mCRC evolution.
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